Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Debra L. Richardson"'
Autor:
Debra L. Richardson
Publikováno v:
Gynecologic Oncology Reports, Vol 46, Iss , Pp 101148- (2023)
Recently, two antibody drug conjugates were FDA approved for the treatment of recurrent gynecologic malignancies. Both of these new agents are associated with ocular toxicity. Ocular toxicity can be prevented and mitigated by utilizing recommended ey
Externí odkaz:
https://doaj.org/article/66aa9609928a4981be8b38f8734d0937
Autor:
Jessica M. Gillen, Sarah C. Grimes, Kathleen G. Essel, Grace E. Duininck, Daniel Zhao, John S. Thompson, Debra L. Richardson
Publikováno v:
Gynecologic Oncology Reports, Vol 34, Iss , Pp 100660- (2020)
We aimed to evaluate how the need for social services programs is associated with outcomes amongst patients with cervical cancer undergoing chemoradiation with a single institution, retrospective analysis of patients from January 1, 2015-July 31, 201
Externí odkaz:
https://doaj.org/article/489172b5587d4a11bf0aad2b86b567c2
Publikováno v:
Gynecologic Oncology Reports, Vol 14, Iss C, p 46 (2015)
Externí odkaz:
https://doaj.org/article/ee3e61fb872d4ab7a99269593bee6972
Autor:
Xiaofei, Zhou, Debra L, Richardson, Afshin, Dowlati, Sanjay, Goel, Solmaz, Sahebjam, James, Strauss, Sant, Chawla, Ding, Wang, Diane R, Mould, Vivek, Samnotra, Douglas V, Faller, Karthik, Venkatakrishnan, Neeraj, Gupta
Publikováno v:
Clinical Pharmacology in Drug Development. 12:257-266
The purpose of this study was to assess the effect of pevonedistat, a neural precursor cell expressed, developmentally down-regulated protein 8 (NEDD8)-activating enzyme inhibitor, on the heart rate-corrected QT (QTc) interval in cancer patients. Pat
Publikováno v:
JAMA Oncology.
ImportancePlatinum-based chemotherapy has been the standard of care for ovarian cancer for the past 3 decades. Although most patients respond to platinum-based treatment, emergence of platinum resistance in recurrent ovarian cancer is inevitable duri
Autor:
Michael J. Birrer, David W. Kindelberger, Helen E. Michael, Debra L. Richardson, Ritu Salani, James J. Burke, Michael L. Pearl, Linda Van Le, Paul DiSilvestro, Eric L. Eisenhauer, Mario M. Leitao, Ana Oaknin, Leslie M. Randall, Lisa M. Landrum, Lois M. Ramondetta, Heather A. Lankes, David H. Moore, Richard T. Penson, Bradley J. Monk, Michael W. Sill, Krishnansu S. Tewari
Supplementary Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b63e127ca6973e30f622840073060f9
https://doi.org/10.1158/1535-7163.22520715
https://doi.org/10.1158/1535-7163.22520715
Autor:
Michael J. Birrer, David W. Kindelberger, Helen E. Michael, Debra L. Richardson, Ritu Salani, James J. Burke, Michael L. Pearl, Linda Van Le, Paul DiSilvestro, Eric L. Eisenhauer, Mario M. Leitao, Ana Oaknin, Leslie M. Randall, Lisa M. Landrum, Lois M. Ramondetta, Heather A. Lankes, David H. Moore, Richard T. Penson, Bradley J. Monk, Michael W. Sill, Krishnansu S. Tewari
To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1 and 36 day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1796369809c7462780e2079b34cca84f
https://doi.org/10.1158/1535-7163.c.6542733
https://doi.org/10.1158/1535-7163.c.6542733
Autor:
Joan Tymon-Rosario, Megan Gorman, Debra L. Richardson, Christina Washington, Alessandro D. Santin
Publikováno v:
Current opinion in obstetricsgynecology.
Antibody-drug conjugates (ADCs) represent a new class of drugs that combine a surface receptor-targeting antibody linked to a cytotoxic molecule delivering the potent cytotoxic payload directly to tumor cells. This review summarizes the current liter
Autor:
Danielle Krause, Debra L. Richardson
Publikováno v:
Current opinion in obstetricsgynecology. 35(1)
Until recently, no data was available from randomized, controlled trials (RCT) to assess the role of secondary cytoreductive surgery (CRS) in the management of recurrent epithelial ovarian cancer. This review highlights results from the three complet
Publikováno v:
Cancer treatment reviews. 112
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment options are limited, particula